Option chain shows key data for Tonix Pharmaceuticals's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Tonix Pharmaceuticals.

Tonix Pharmaceuticals (NASDAQ:TNXP) Stock, Option Chain

Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.

Intel, Cleanspark, Super Micro Computer, Upstart, Tesla: Why These 5 Stocks Are On Investors' Radars Today

Earnings

News

Markets

Trading Ideas

APDN

AUID

CERO

COMM

CRVS

EFSH

FSBW

NIVF

NUKK

PRTG

PRZO

PTPI

RZLV

SHLT

SSBK

TNXP

VSTE

Why Corvus Pharmaceuticals Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket

Pharmaceutics,Laboratory:,Pipette,Dropping,Yellow,Liquid,Into,Test,Tubes,,Medical

Movers

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) shares are trading lower Tuesday after initially jumping after the company announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) for TNX-102 SL, a 5.6 mg non-opioid. Here&#39;s what you need to know.

What&#39;s Going On With Tonix Pharmaceuticals Stock Today?

Energy stocks

Equities

Eurozone

Commodities

DBGI

QUBT

TNYA

VCNX

Crude Oil Down Over 1%; US Industrial Production Declines In November

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals Holding Corp

<h3>Gainers</h3>
<ul>
<li>Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) shares rose 148.4% to $1.13 during Wednesday's pre-market session. The market value of their outstanding shares is at $46.9 million. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares increased by 140.95% to $2.53. The company's market cap stands at $10.6 million. </li>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) stock increased by 68.18% to $0.79. The company's market cap stands at $6.4 million. </li>
<li>CERo Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) shares rose 44.02% to $0.09. The company's market cap stands at $13.2 million. </li>
<li>Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) shares increased by 22.79% to $0.41. The company's market cap stands at $76.6 million. </li>
<li>Evaxion Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVAX#NASDAQ">EVAX</a>) shares rose 18.09% to $1.13. The company's market cap stands at $6.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Petros Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) shares decreased by 34.8% to $0.33 during Wednesday's pre-market session. The company's market cap stands at $3.2 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) stock fell 33.5% to $4.2. The market value of their outstanding shares is at $2.9 million. </li>
<li>Corvus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) stock fell 31.53% to $5.06. The market value of their outstanding shares is at $325.1 million. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares declined by 23.32% to $0.32. The market value of their outstanding shares is at $4.4 million. </li>
<li>Radiopharm Theranostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RADX#NASDAQ">RADX</a>) shares fell 21.66% to $3.51. The company's market cap stands at $7.6 billion. </li>
<li>SI-BONE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIBN#NASDAQ">SIBN</a>) stock fell 20.53% to $11.0. The company's market cap stands at $461.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CGTX

EVAX

PLRZ

RADX

RNAZ

SIBN

TCBP

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) rose sharply in today's pre-market trading after the company announced it will report on December 18 interim data from its Phase 1 clinical trial evaluating Soquelitinib in patients with moderate to<a href="https://www.benzinga.com/quote/CRVS"> severe atopic dermatitis</a>.
Corvus Pharmaceuticals shares jumped 22.5% to $9.06 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>ParaZero Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRZO#NASDAQ">PRZO</a>) gained 88.8% to $2.89 in pre-market trading after gaining 5% on Tuesday. ParaZero Technologies regained Nasdaq compliance.</li>
<li>Vast Renewables Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTE#NASDAQ">VSTE</a>) climbed 68.4% to $2.19 in pre-market trading after declining over 6% on Tuesday.</li>
<li>Nukkleus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUKK#NASDAQ">NUKK</a>) gained 55.1% to $18.42 in pre-market trading. Nukkleus shares jumped 755% on Tuesday after the company announced it has acquired a 51% controlling stake in Star 26 Capital.</li>
<li>1847 Holdings LLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EFSH#NASDAQ">EFSH</a>) gained 46% to $0.3278 in pre-market trading.</li>
<li>Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) rose 33% to $0.4417 in pre-market trading after dipping 37% on Tuesday.</li>
<li>Rezolve AI Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLV#NASDAQ">RZLV</a>) gained 30.1% to $4.28 in pre-market trading.</li>
<li>CERo Therapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) gained 27.7% to $0.0780 in pre-market trading after jumping 20% on Tuesday.</li>
<li>Richtech Robotics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RR#NASDAQ">RR</a>) gained 26% to $1.55 in pre-market trading after jumping over 26% on Tuesday.</li>
<li>CommScope Holding Company, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COMM#NASDAQ">COMM</a>) rose 9.1% to $6.12 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>NewGenIvf Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares tumbled 29.9% to $0.30 in pre-market trading after jumping 56% on Tuesday.</li>
<li>Petros Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) declined 24% to $0.38 in pre-market trading after jumping 87% on Tuesday.</li>
<li>KWESST Micro Systems Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KWE#NASDAQ">KWE</a>) shares fell 15.5% to $0.71 in pre-market trading after surging over 15% on Tuesday.</li>
<li>Applied DNA Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) shares fell 14.7% to $0.1962 in pre-market trading after reporting weak quarterly sales.</li>
<li>authID Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUID#NASDAQ">AUID</a>) dipped 13.8% to $5.00 in pre-market trading following a 4% decline in the previous session.</li>
<li>FS Bancorp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSBW#NASDAQ">FSBW</a>) fell 13.4% to $39.01 in pre-market trading.</li>
<li>Portage Biotech Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) fell 12.5% to $7.90 in today's pre-market trading after jumping 182% on Tuesday.</li>
<li>SHL Telemedicine Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLT#NASDAQ">SHLT</a>) fell 10% to $3.15 in pre-market trading following a 20% surge on Tuesday.</li>
<li>Southern States Bancshares, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSBK#NASDAQ">SSBK</a>) fell 9.6% to $32.00 in pre-market trading.</li>
<li>Worthington Steel, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WS#NYSE">WS</a>) shares dipped 8.6% to $36.00 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42531171/top-2-utilities-stocks-that-could-sink-your-portfolio-this-quarter">Top 2 Utilities Stocks That Could Sink Your Portfolio This Quarter</a></li>
</ul>

<h3>Gainers</h3>
<ul>
<li>Portage Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) shares increased by 178.2% to $9.04 during Tuesday's pre-market session. The company's market cap stands at $10.1 million. </li>
<li>Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) shares moved upwards by 137.73% to $1.26. The market value of their outstanding shares is at $235.4 million. </li>
<li>Camp4 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>) shares rose 39.15% to $8.85. The company's market cap stands at $178.4 million. </li>
<li>Akari Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKTX#NASDAQ">AKTX</a>) stock rose 27.53% to $1.26. The market value of their outstanding shares is at $33.3 million. </li>
<li>Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) shares moved upwards by 19.13% to $19.67. The market value of their outstanding shares is at $22.2 billion. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock rose 17.99% to $1.18. The market value of their outstanding shares is at $4.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Vaccinex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCNX#NASDAQ">VCNX</a>) stock decreased by 47.7% to $1.91 during Tuesday's pre-market session. The market value of their outstanding shares is at $5.1 million. </li>
<li>Reviva Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVPH#NASDAQ">RVPH</a>) shares decreased by 38.27% to $1.42. The company's market cap stands at $47.4 million. </li>
<li>PepGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEPG#NASDAQ">PEPG</a>) shares decreased by 33.49% to $3.0. The market value of their outstanding shares is at $97.7 million. </li>
<li>Tenaya Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNYA#NASDAQ">TNYA</a>) stock declined by 31.25% to $1.98. The company's market cap stands at $156.8 million. </li>
<li>LeMaitre Vascular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMAT#NASDAQ">LMAT</a>) stock declined by 23.79% to $70.19. The market value of their outstanding shares is at $1.5 billion. </li>
<li>Biomea Fusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) shares decreased by 12.49% to $5.12. The company's market cap stands at $185.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKTX

BMEA

CAMP

LMAT

PEPG

RVPH

TEVA

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Tonix Pharmaceuticals Holding Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) shares are trading lower Tuesday after initially jumping after the company announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) for TNX-102 SL, a 5.6 mg non-opioid. Here&#8217;s <a href="https://www.benzinga.com/quote/TNXP/news">what you need to know.</a>
What To Know: The FDA&#8217;s acceptance of the NDA triggers a process in which the agency will assign a Prescription Drug User Fee Act (PDUFA) target action date and determine if the application qualifies for priority review, which will be communicated in the Day 74 Letter. TNX-102 SL was granted Fast Track designation by the FDA in July 2024.
Fibromyalgia affects more than 10 million adults in the United States, with the majority being women. TNX-102 SL, if approved, could be the first new drug for treating fibromyalgia in over 15 years and the first member of a new class of analgesic drugs for the condition.
The NDA submission is supported by two Phase 3 studies — RELIEF and RESILIENT — that evaluated TNX-102 SL&#8217;s safety and efficacy. Both trials met their primary endpoints, demonstrating a statistical reduction in daily pain compared to placebo. 
In the RELIEF study completed in December 2020, results showed significance with a p-value of 0.010. In the confirmatory RESILIENT trial completed in December 2023, significance was observed with a p-value of 0.00005. TNX-102 SL was generally well tolerated in both trials. The most common treatment-related adverse event was temporary numbness of the tongue or mouth at the administration site, which did not lead to significant study discontinuations.
See Also: <a href="https://www.benzinga.com/news/retail-sales/24/12/42535296/stocks-slip-as-strong-november-retail-sales-raise-concerns-over-2025-fed-rate-cuts">Stocks Slip As Strong November Retail Sales Raise Concerns Over 2025 Fed Rate Cuts</a>
Tonix Pharmaceuticals&#8217; CEO Seth Lederman noted that the fibromyalgia community has been waiting for a new drug for over 15 years and emphasized that, based on U.S. insurance claims data, fibromyalgia patients are more likely to be prescribed opioids than all three current FDA-approved drugs combined within 18 months of diagnosis.
Tonix is preparing for potential approval in 2025. The company noted that it already has a commercial leadership team in place. Tonix also markets Zembrace SymTouch (sumatriptan injection) and Tosymra (sumatriptan nasal spray) for the acute treatment of migraine.
TNXP Price Action: Tonix shares were up about 25% for the session at the time of writing, but had turned negative by publication time. At last check, Tonix shares were down 7.11% at 49 cents, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
Image Via Shutterstock.

What's Going On With Tonix Pharmaceuticals Stock Today?

U.S. stocks traded lower midway through trading, with the S&amp;P 500 falling around 0.3% on Tuesday.
The Dow traded down 0.59% to 43,459.99 while the NASDAQ fell 0.15% to 20,143.34. The S&amp;P 500 also fell, dropping, 0.28% to 6,057.00.
Check This Out: <a href="https://www.benzinga.com/24/12/42527883/top-3-financial-stocks-which-could-rescue-your-portfolio-for-december">Top 3 Financial Stocks Which Could Rescue Your Portfolio For December</a>
Leading and Lagging Sectors Communication services shares rose by 0.3% on Tuesday.
In trading on Tuesday, energy shares fell by 1.4%.
Top Headline
U.S. industrial production declined by 0.1% from the previous month in November compared to a 0.4% drop in October, and versus market estimates of a 0.2% gain.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Portage Biotech Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) shares shot up 109% to $6.69 after the company announced it entered a letter of intent with Immunova for potential acquisitions.</li>
<li>Shares of Quantum Computing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) got a boost, surging 38% to $15.24 after the company announced it was awarded a prime contract by NASA to apply Dirac-3 for imaging and data processing support.</li>
<li>Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) shares were also up, gaining 22% to $0.6461 after the company announced FDA acceptance for its TNX-102 SL drug application Fibromyalgia.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Vaccinex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCNX#NASDAQ">VCNX</a>) shares dropped 62% to $1.40 after the company reported Nasdaq delisting notification.</li>
<li>Shares of Digital Brands Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBGI#NASDAQ">DBGI</a>) were down 29% to $2.8201. On Monday, Digital Brands Group issued FY25 guidance.</li>
<li>Tenaya Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNYA#NASDAQ">TNYA</a>) was down, falling 53% to $1.3550 after the company reported early results for gene therapy in heart disease.</li>
</ul>
Commodities In commodity news, oil traded down 1.6% to $69.56 while gold traded down 0.5% at $2,655.80.
Silver traded down 0.4% to $30.925 on Tuesday, while copper fell 1.3% to $4.1385.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 fell 0.42%, Germany's DAX fell 0.33% and France's CAC 40 rose 0.12%. Spain's IBEX 35 Index dipped 1.52%, while London's FTSE 100 fell 0.81%.
Asia Pacific Markets
Asian markets closed lower on Tuesday, with Japan's Nikkei 225 falling 0.24%, Hong Kong's Hang Seng Index dipping 0.48%, China's Shanghai Composite Index falling 0.73% and India's BSE Sensex falling 1.30%.
Economics
<ul>
<li>U.S. retail sales rose 0.7% month-over-month in November compared to a revised 0.5% gain in the previous month and above market estimates of 0.5%.</li>
<li>U.S. industrial production declined by 0.1% from the previous month in November compared to a 0.4% drop in October, and versus market estimates of a 0.2% gain.</li>
<li>U.S. business inventories increased by 0.1% month-over-month in October following a revised flat reading a month ago.</li>
<li>The NAHB/Wells Fargo Housing Market Index came in unchanged at 46 in December.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42527585/this-tesla-analyst-turns-bullish-here-are-top-5-upgrades-for-tuesday">This Tesla Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday</a></li>
</ul>

Tonix Pharmaceuticals Shares Halted For Volatility

U.S. stocks traded lower this morning, with the Dow Jones index falling more than 200 points on Tuesday.
Following the market opening Tuesday, the Dow traded down 0.50% to 43,498.72 while the NASDAQ fell 0.55% to 20,062.78. The S&amp;P 500 also fell, dropping, 0.49% to 6,044.48.
Check This Out: <a href="https://www.benzinga.com/24/12/42527883/top-3-financial-stocks-which-could-rescue-your-portfolio-for-december">Top 3 Financial Stocks Which Could Rescue Your Portfolio For December</a>
Leading and Lagging Sectors Health care shares rose by 0.3% on Tuesday.
In trading on Tuesday, energy shares fell by 1.2%.
Top Headline
U.S. retail sales rose 0.7% month-over-month in November compared to a revised 0.5% gain in the previous month and above market estimates of 0.5%.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Portage Biotech Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) shares shot up 176% to $8.49 after the company announced it entered a letter of intent with Immunova for potential acquisitions.</li>
<li>Shares of Syntec Optics Holdings, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTX#NASDAQ">OPTX</a>) got a boost, surging 129% to $4.1399 after adding more than 80% on Monday.</li>
<li>Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) shares were also up, gaining 112% to $1.13 after the company announced FDA acceptance for its TNX-102 SL drug application Fibromyalgia.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Vaccinex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCNX#NASDAQ">VCNX</a>) shares dropped 57% to $1.61 after the company reported Nasdaq delisting notification.</li>
<li>Shares of Digital Brands Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBGI#NASDAQ">DBGI</a>) were down 46% to $2.12. On Monday, Digital Brands Group issued FY25 guidance.</li>
<li>Tenaya Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNYA#NASDAQ">TNYA</a>) was down, falling 44% to $1.61 after the company reported early results for gene therapy in heart disease.</li>
</ul>
Commodities In commodity news, oil traded down 1.1% to $69.94 while gold traded down 0.5% at $2,657.90.
Silver traded down 1.1% to $30.720 on Tuesday, while copper fell 1.1% to $4.1450.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 fell 0.5%, Germany's DAX fell 0.2% and France's CAC 40 rose 0.1%. Spain's IBEX 35 Index dipped 1.3%, while London's FTSE 100 fell 0.8%.
Asia Pacific Markets
Asian markets closed lower on Tuesday, with Japan's Nikkei 225 falling 0.24%, Hong Kong's Hang Seng Index dipping 0.48%, China's Shanghai Composite Index falling 0.73% and India's BSE Sensex falling 1.30%.
Economics
U.S. retail sales rose 0.7% month-over-month in November compared to a revised 0.5% gain in the previous month and above market estimates of 0.5%. 
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42527585/this-tesla-analyst-turns-bullish-here-are-top-5-upgrades-for-tuesday">This Tesla Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday</a></li>
</ul>

Intraday Update

OPTX

Dow Dips Over 200 Points; US Retail Sales Top Estimates

Trading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times

General

Tonix Pharmaceuticals shares are trading higher after the company announced FDA acceptance for its TNX-102 SL drug application Fibromyalgia.

Tonix Pharmaceuticals Announces FDA Acceptance Of Its New Drug Application For TNX-102 SL In Fibromyalgia; Says FDA Expected To Assign A PDUFA Target Action Date And Announce Whether Priority Review Has Been Granted In The Day 74 Letter

Trading Halt: Halted at 7:31:17 a.m. ET - Trading Halt: Halt News Pending

Shares of Mitek Systems, Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MITK#NASDAQ">MITK</a>) rose sharply in today's pre-market trading after reporting <a href="https://www.benzinga.com/quote/MITK/earnings">better-than-expected fourth-quarter results.</a>
Mitek Systems reported quarterly earnings of 33 cents per share which beat the analyst consensus estimate of 17 cents per share. The company reported quarterly sales of $43.222 million which beat the analyst consensus estimate of $41.306 million.
Mitek Systems shares jumped 18.8% to $11.28 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Syntec Optics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTX#NASDAQ">OPTX</a>) gained 59% to $2.83 in pre-market trading after adding more than 80% on Monday.</li>
<li>Maison Solutions Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSS#NASDAQ">MSS</a>) gained 65.3% to $1.72 in pre-market trading after the company reported financial results for the second quarter and six-months ended Oct. 31.</li>
<li>KWESST Micro Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KWE#NASDAQ">KWE</a>) gained 44.6% to $1.05 in pre-market trading after surging around 15% on Monday.</li>
<li>SEALSQ Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAES#NASDAQ">LAES</a>) rose 27.8% to $3.13 in pre-market trading after surging 40% on Monday. SEALSQ announced the pricing of $25.0 million registered direct offering priced above market under NASDAQ rules.</li>
<li>Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) gained 23.5% to $0.6550 in pre-market trading after jumping 120% on Monday.</li>
<li>Sidus Space, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIDU#NASDAQ">SIDU</a>) climbed 21.5% to $5.57 in pre-market trading after jumping 220% on Monday.</li>
<li>Gryphon Digital Mining Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRYP#NASDAQ">GRYP</a>) gained 17% to $0.60 in pre-market trading after falling 8% on Monday.</li>
<li>SolarEdge Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) gained 10.5% to $13.62 in pre-market trading after falling around 8% on Monday.</li>
<li>Cango Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CANG#NYSE">CANG</a>) gained 9.7% to $6.02 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVPH#NASDAQ">RVPH</a>) shares tumbled 29.6% to $1.62 in pre-market trading after the company reported the pricing of $18.0 million public offering of common stock and warrants.</li>
<li>Mama&#8217;s Creations Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAMA#NASDAQ">MAMA</a>) declined 17.9% to $7.96 in pre-market trading after the company reported worse-than-expected third-quarter EPS results.</li>
<li>EVgo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGO#NASDAQ">EVGO</a>) shares fell 16.1% to $5.30 in pre-market trading after the company announced a secondary offering of 23 million shares.</li>
<li>Webuy Global Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBUY#NASDAQ">WBUY</a>) shares fell 14.1% to $0.1950 in pre-market trading after jumping 29% on Monday. Webuy Global announced the pricing of $3.7 million registered direct offering.</li>
<li>NAYA Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAYA#NASDAQ">NAYA</a>) dipped 13.1% to $0.7042 in pre-market trading.</li>
<li>Digital Brands Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBGI#NASDAQ">DBGI</a>) fell 13.1% to $3.44 in pre-market trading after gaining over 7% on Monday.</li>
<li>Alset Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEI#NASDAQ">AEI</a>) fell 12.4% to $0.9197 in pre-market trading following a 4% decline on Monday.</li>
<li>Celcuity Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELC#NASDAQ">CELC</a>) fell 12.3% to $11.01 in today's pre-market trading.</li>
<li>Petros Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) fell 9.6% to $0.2415 in pre-market trading after dipping 18% on Monday.</li>
<li>Palmer Square Capital BDC Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSBD#NYSE">PSBD</a>) shares dipped 6% to $15.04 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/12/42507875/how-to-earn-500-a-month-from-worthington-enterprises-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Worthington Enterprises Stock Ahead Of Q2 Earnings</a></li>
</ul>

Pre-Market Outlook

CANG

CELC

EVGO

GRYP

LAES

MAMA

MITK

Merrill Lynch & Strategic Return Notes for Select 10 Index

NAYA

PSBD

SEDG

SIDU

WBUY

Why Mitek Systems Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket

<h3>Gainers</h3>
<ul>
<li>Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) stock increased by 25.3% to $0.3 during Monday's pre-market session. The company's market cap stands at $56.3 million. </li>
<li>Viridian Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRDN#NASDAQ">VRDN</a>) stock rose 18.2% to $21.1. The company's market cap stands at $1.6 billion. </li>
<li>Sagimet Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMT#NASDAQ">SGMT</a>) shares rose 17.99% to $5.18. The market value of their outstanding shares is at $166.7 million. </li>
<li>PureTech Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTC#NASDAQ">PRTC</a>) shares rose 15.42% to $23.49. The market value of their outstanding shares is at $562.4 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) shares rose 15.26% to $0.21. The company's market cap stands at $6.6 million. </li>
<li>FibroBiologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBLG#NASDAQ">FBLG</a>) stock moved upwards by 14.41% to $2.54. The company's market cap stands at $88.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>PepGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEPG#NASDAQ">PEPG</a>) stock decreased by 35.9% to $3.0 during Monday's pre-market session. The company's market cap stands at $97.7 million. </li>
<li>Larimar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRMR#NASDAQ">LRMR</a>) stock fell 34.53% to $4.04. The company's market cap stands at $257.7 million. </li>
<li>Innate Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPHA#NASDAQ">IPHA</a>) shares declined by 16.23% to $2.53. The company's market cap stands at $209.4 million. </li>
<li>LakeShore Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSB#NASDAQ">LSB</a>) stock declined by 12.23% to $2.19. The company's market cap stands at $41.7 million. </li>
<li>Foghorn Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FHTX#NASDAQ">FHTX</a>) shares fell 11.51% to $4.69. The market value of their outstanding shares is at $259.4 million. </li>
<li>Palisade Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALI#NASDAQ">PALI</a>) stock fell 11.38% to $1.57. The company's market cap stands at $2.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FBLG

FHTX

IPHA

Larimar Therapeutics, Inc. - Common Stock

LRMR

PALI

PRTC

SGMT

VRDN

12 Health Care Stocks Moving In Monday's Pre-Market Session

Shares of Edgewise Therapeutics, Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWTX#NASDAQ">EWTX</a>) rose sharply in today's pre-market trading after the company reported topline results from Phase 2 CANYON trial of Sevasemten in individuals with <a href="https://www.benzinga.com/quote/EWTX/news">becker muscular dystrophy</a>.
Edgewise Therapeutics shares jumped 26.5% to $35.00 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Sidus Space, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIDU#NASDAQ">SIDU</a>) gained 59.4% to $2.28 in pre-market trading after adding 9% on Friday.</li>
<li>SEALSQ Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAES#NASDAQ">LAES</a>) gained 48.6% to $2.60 in pre-market trading after falling over 5% on Friday.</li>
<li>U-BX Technology Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBXG#NASDAQ">UBXG</a>) gained 32.3% to $4.40 in pre-market trading.</li>
<li>PureTech Health plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTC#NASDAQ">PRTC</a>) rose 22.8% to $25.00 in pre-market trading after the company reported positive results from ELEVATE IPF, a Phase 2b randomized, double-blind, active- and placebo-controlled, dose-ranging trial evaluating deupirfenidone (LYT-100) at two dose levels three times a day (TID) over 26 weeks in patients with idiopathic pulmonary fibrosis (IPF).</li>
<li>BTC Digital Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTCT#NASDAQ">BTCT</a>) gained 22.8% to $7.84 in pre-market trading.</li>
<li>Sagimet Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMT#NASDAQ">SGMT</a>) climbed 17.2% to $5.15 in pre-market trading after falling over 3% on Friday.</li>
<li>Kratos Defense &amp; Security Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTOS#NASDAQ">KTOS</a>) gained 14.4% to $30.72 in pre-market trading.</li>
<li>Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) gained 13.8% to $0.2736 in pre-market trading after gaining 5% on Friday.</li>
<li>BitFuFu Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUFU#NASDAQ">FUFU</a>) gained 9.1% to $5.64 in pre-market trading following a 9% decline on Friday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Akoustis Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKTS#NASDAQ">AKTS</a>) shares tumbled 39.8% to $0.0410 in pre-market trading after the company filed for Chapter 11 and initiated strategic sale of business amid Qorvo legal dispute.</li>
<li>Roadzen, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDZN#NASDAQ">RDZN</a>) declined 32.6% to $1.20 in pre-market trading after the company priced its $2.5 million public offering of 2 million common shares at $1.25 per share.</li>
<li>SMX (Security Matters) Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMX#NASDAQ">SMX</a>) shares fell 23.9% to $0.2160 in pre-market trading after the company announced the receipt of Nasdaq Listing Delinquency Notice.</li>
<li>Karyopharm Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) fell 21.6% to $0.55 in pre-market trading.</li>
<li>AtlasClear Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATCH#NASDAQ">ATCH</a>) dipped 20.5% to $0.1750 in pre-market trading.</li>
<li>Innate Pharma S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPHA#NASDAQ">IPHA</a>) shares dipped 19.2% to $2.44 in pre-market trading after jumping 96% on Friday. The company, last week. announced its TELLOMAK Phase 2 trial of Lacutamab demonstrated significant symptom relief and quality of life improvements.</li>
<li>22nd Century Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) shares fell 17.5% to $0.0404 in pre-market trading after dipping 33% on Friday.</li>
<li>Santech Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STEC#NASDAQ">STEC</a>) fell 17.2% to $0.63 in pre-market trading.</li>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) fell 12.5% to $31.85 in pre-market trading following reports suggesting the company tapped Evercore to raise capital and is considering raising equity and debt.</li>
<li>SPI Energy Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPI#NASDAQ">SPI</a>) fell 12.1% to $0.34 in today's pre-market trading after jumping over 10% on Friday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42482639/wall-streets-most-accurate-analysts-give-their-take-on-3-energy-stocks-with-over-6-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Energy Stocks With Over 6% Dividend Yields</a></li>
</ul>

AKTS

ATCH

BTCT

EWTX

FUFU

KPTI

KTOS

RDZN

SMCI

STEC

UBXG

XXII

Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket

Tonix Pharmaceuticals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NYSE">TNXP</a>) short percent of float has fallen 69.53% since its last report. The company recently reported that it has 1.59 million shares sold short, which is 0.85% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Tonix Pharmaceuticals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734013816_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Tonix Pharmaceuticals has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Tonix Pharmaceuticals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Tonix Pharmaceuticals's peer group average for short interest as a percentage of float is 4.37%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Tonix Pharmaceuticals?

<a href="https://scr.zacks.com/files/News/2024/Zacks_SCR_Research_12032024_TNXP_Bautz.pdf" title="https://scr.zacks.com/files/News/2024/Zacks_SCR_Research_12032024_TNXP_Bautz.pdf">https://scr.zacks.com/files/News/2024/Zacks_SCR_Research_12032024_TNXP_Bautz.pdf</a>

Analyst Ratings

Watching Tonix Pharmaceuticals; Zacks Small-Cap Research Gives Stock $2.50 Price Valuation

<a href="https://worldhealthorg.shinyapps.io/mpx_global/" title="https://worldhealthorg.shinyapps.io/mpx_global/">https://worldhealthorg.shinyapps.io/mpx_global/</a>

Biotech

AEMD

CMRX

GOVX

VRAX

World Health Organization Says Mpox Continues To Constitute A Public Health Emergency Of International Concern

Tonix Pharmaceuticals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NYSE">TNXP</a>) short percent of float has risen 40.51% since its last report. The company recently reported that it has 7.67 million shares sold short, which is 5.48% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Tonix Pharmaceuticals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732294819_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Tonix Pharmaceuticals has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Tonix Pharmaceuticals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Tonix Pharmaceuticals's peer group average for short interest as a percentage of float is 5.21%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Tonix Pharmaceuticals's Recent Short Interest

<h3>Gainers</h3>
<ul>
<li>Quantum-Si (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSI#NASDAQ">QSI</a>) stock rose 144.9% to $1.55 during Wednesday's pre-market session. The company's market cap stands at $221.2 million. </li>
<li>Forte Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBRX#NASDAQ">FBRX</a>) shares moved upwards by 76.53% to $10.46. The company's market cap stands at $15.2 million. The company's, Q3 earnings came out 4 days ago. </li>
<li>Silexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) stock rose 72.36% to $0.39. The company's market cap stands at $5.6 million. As per the news, the Q3 earnings report came out 4 days ago. </li>
<li>Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) shares moved upwards by 57.59% to $0.26. The market value of their outstanding shares is at $47.9 million. </li>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) shares rose 21.13% to $7.05. The company's market cap stands at $15.3 million. As per the press release, Q3 earnings came out 4 days ago. </li>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) shares moved upwards by 19.85% to $1.63. The company's market cap stands at $278.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Lineage Cell Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LCTX#AMEX">LCTX</a>) shares declined by 19.7% to $0.72 during Wednesday's pre-market session. The company's market cap stands at $136.9 million. As per the press release, Q3 earnings came out 4 days ago. </li>
<li>Apollomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLM#NASDAQ">APLM</a>) shares declined by 17.23% to $0.14. The company's market cap stands at $14.9 million. </li>
<li>BrightSpring Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTSGU#NASDAQ">BTSGU</a>) stock declined by 16.86% to $56.38. </li>
<li>Oncology Institute (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOI#NASDAQ">TOI</a>) stock fell 15.56% to $0.15. The market value of their outstanding shares is at $11.4 million. </li>
<li>HCW Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) shares declined by 15.35% to $0.93. The market value of their outstanding shares is at $35.2 million. As per the news, the Q3 earnings report came out 4 days ago. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) shares decreased by 13.93% to $0.1. The market value of their outstanding shares is at $8.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APLM

BTSGU

EYEN

FBRX

HCWB

LCTX

SLXN

TVGN

XCUR

Shares of Keysight Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEYS#NYSE">KEYS</a>) rose sharply in today's pre-market trading reported <a href="https://www.benzinga.com/news/earnings/24/11/42075636/keysight-technologies-stock-jumps-on-q4-earnings-revenue-beat-eps-beat-confidence-in-our-ability-to-outperform">better-than-expected earnings for its fourth quarter.</a>
Keysight reported quarterly earnings of $1.65 per share which beat the analyst consensus estimate of $1.57. The company reported quarterly sales of $1.287 billion which beat the analyst consensus estimate of $1.258 billion.
The company said it sees first-quarter revenue of $1.265 billion to $1.285 billion and adjusted earnings of $1.65 to $1.71 per share.
Keysight shares jumped 9.3% to $166.20 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) gained 63.6% to $0.2663 in pre-market trading after jumping 22% on Tuesday.</li>
<li>Nauticus Robotics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KITT#NASDAQ">KITT</a>) rose 59.3% to $1.45 in pre-market trading after the company entered into strategic collaboration with SeaTrepid to integrate and test its ToolKITT software on remotely operated vehicles.</li>
<li>Tevogen Bio Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) gained 41.2% to $1.92 in pre-market trading following third-quarter results.</li>
<li>Digital Brands Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBGI#NASDAQ">DBGI</a>) gained 30.7% to $0.1524 in pre-market trading after jumping around 18% on Tuesday.</li>
<li>JX Luxventure Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JXJT#NASDAQ">JXJT</a>) gained 26.2% to $1.64 in pre-market trading after declining around 12% on Tuesday.</li>
<li>KORE Group Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KORE#NYSE">KORE</a>) gained 25.1% to $2.29 in pre-market trading after the company reported better-than-expected quarterly sales results.</li>
<li>Algorhythm Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIME#NASDAQ">RIME</a>) gained 23.4% to $0.3150 in pre-market trading after reporting third-quarter results.</li>
<li>Hoth Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOTH#NASDAQ">HOTH</a>) climbed 22.2% to $0.9993 in pre-market trading after the company was granted U.S. Patent No. 12,144,815 titled &#8220;Use of Aprepitant for Treating Alzheimer&#8217;s Disease.&#8221;</li>
<li>Kingsoft Cloud Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) gained 20.8% to $5.55 in pre-market trading. Kingsoft Cloud, on Tuesday, reported a fiscal third-quarter 2024 revenue of 1.89 billion Chinese yuan ($268.7 million), up by 16.0% year-on-year, beating the analyst consensus estimate of $247.46 million.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>PainReform Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRFX#NASDAQ">PRFX</a>) shares tumbled 26.4% to $1.03 in pre-market trading after jumping 162% on Tuesday. The company announced a 1-for-4 reverse stock split.</li>
<li>X3 Holdings Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTKG#NASDAQ">XTKG</a>) fell 27.4% to $0.1050 in pre-market trading. XTKG announced a 1-for-20 share consolidation.</li>
<li>Solidion Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STI#NASDAQ">STI</a>) shares fell 21.2% to $0.5003 in pre-market trading following third-quarter results.</li>
<li>Volato Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOAR#NYSE">SOAR</a>) declined 16.7% to $0.3912 in pre-market trading after jumping 123% on Tuesday. Volato Group, on Monday, reported a year-over-year increase in third-quarter financial results.</li>
<li>HCW Biologics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) shares fell 16.6% to $0.9180 in pre-market trading after dipping 11% on Tuesday. The company announced a $6.9 million direct offering and private placement.</li>
<li>Powell Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWL#NASDAQ">POWL</a>) dipped 15.4% to $264.00 in pre-market trading after the company reported worse-than-expected fourth-quarter revenue results.</li>
<li>Destiny Tech100 Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXYZ#NASDAQ">DXYZ</a>) shares dipped 13.4% to $39.18 in pre-market trading after jumping 24% on Tuesday.</li>
<li>Workhorse Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKHS#NASDAQ">WKHS</a>) fell 13.1% to $1.06 in pre-market trading after posting quarterly results.</li>
<li>Silvercorp Metals Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SVM#NYSE">SVM</a>) fell 11.3% to $3.59 in pre-market trading after the company announced a $130 million convertible senior notes offering.</li>
<li>QuidelOrtho Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>) fell 6.7% to $36.01 in today's pre-market trading after the company announced the pricing of secondary offering of common stock by the Carlyle Group.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/24/11/42069785/wall-streets-most-accurate-analysts-weigh-in-on-3-defensive-stocks-with-over-5-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Defensive Stocks With Over 5% Dividend Yields</a></li>
</ul>

DXYZ

HOTH

JXJT

KEYS

KITT

KORE

POWL

PRFX

QDEL

RIME

SOAR

WKHS

XTKG

Why Keysight Technologies Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket

First mpox case linked to African outbreak reported in U.S.

Tonix Pharmaceuticals (TNXP) presented data in a poster presentation at the ACR Convergence 2024 Annual Meeting, held November 14-19, 2024, in Wash...

Tonix Pharmaceuticals presents data, analyses of TNX-102 SL effects

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

WHO extends mpox emergency; Canada reports first Clade I case

Tonix Pharma ( ($TNXP) ) just unveiled an announcement. Tonix Pharmaceuticals is strategically strengthening its leadership team by appointing new ...

Tonix Pharma Expands Leadership Amid Drug Development

Tonix Pharmaceuticals (TNXP) Holding announced the expansion of its leadership team to support the launch of TNX-102 SL for the management of fibro...

Tonix Pharmaceuticals appoints Raudabaugh, Gould as VPs

Tonix Pharmaceuticals (TNXP) announced that the U.S. Food and Drug Administration, FDA, has accepted the filing of its New Drug Application, NDA, f...

Tonix Pharmaceuticals announces FDA acceptance of NDA for TNX-102 SL

Tonix Pharma ( ($TNXP) ) has provided an announcement. Tonix Pharmaceuticals announced the FDA's acceptance of its New Drug Application for TNX-102...

Tonix Pharma's TNX-102 SL Nears FDA Approval Milestone

Tonix jumps as pain therapy accepted for FDA review

ACRS

APLS

APVO

BVNKF

BVNRY

CHRS

CKPT

CODX

INCY

RHHBF

RHHBY

SGMO

SIGA

Untitled design - 2024-12-07T011441.837

Tonix&#39;s TNX 102-SL Could Offer New Hope Of Pain Relief Without Narcotics For Fibromyalgia Sufferers

Screenshot 2024-11-13 at 11.54.41 PM

ABBV

Tonix Pharmaceuticals Targets Rapid Migraine Relief With Non-Oral Treatments

Screenshot 2024-09-30 at 9.13.36 PM

VRTX

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-09-18 at 12.30.33 AM

New Hope For Mpox? How TNX-801 Could Meet The WHO&#39;s Vaccine Targets For A Safer, Single-Dose Solution

Untitled design - 2024-09-04T162950.621

As Research Into Pain Accelerates, A Newly Recognized Type Of Pain Comes To The Forefront – Tonix Targets It With FDA-Fast Track-Designated TNX-102 SL

Screenshot 2024-08-23 at 3.09.59 AM

Modern Twist To Centuries-Old Smallpox Vaccine Could Be Poised To Combat Deadly Mpox Strain As WHO Declares Global Emergency

Screenshot 2024-08-01 at 5.06.20 PM

FDA Recognizes Fibromyalgia As A &#39;Serious Condition&#39; And Fast-Tracks New Drug Candidate

Screenshot 2024-07-23 at 10.19.53 PM

Beyond &#34;One Bug, One Drug&#34; – Tonix Pharmaceuticals Secures Up To $34 Million In Funding From U.S. Department Of Defense To Develop Broad-Spectrum Antiviral

Comments

Tonix Pharmaceuticals

Tonix Pharmaceuticals (TNXP) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga